Manufacturing of Monoclonal Antibody for COVID-19 Scaled Up by Humanigen, Thermo Fisher
September 24, 2020
By Neozene

The following article originally appeared in FiercePharma and was written by Kyle Blankenship In the earliest days of the COVID-19 pandemic, a suite of drugmakers looked to monoclonal antibodies to fight the immune system overreaction seen in severe patients. Months later, most of those candidates have had mixed success, but Humanigen is pressing ahead—and it’s bringing on partners to help scale for market. Humanigen has tapped Thermo Fisher Scientific to help scale up manufacturing of the California biotech’s lenlizumab, a clinical-stage candidate for cytokine storm that the company is testing in severe

Pandemic is Best Chance for Big Pharma to Fix Reputation: Brand Expert
September 17, 2020
By Neozene

The following article originally appeared in FiercePharma and was written by Beth Snyder Bulik It’s a once-in-a-generation opportunity for the pharma industry. Reputation and trust are at an all-time high as consumers look to drugmakers for vaccines and treatments that can clear a path out of the COVID-19 pandemic. Don’t break out the champagne just yet, though, warns one branding expert. The door may be open to long-term image repair, but pharma companies have to make real changes, said Interbrand Health Executive Director Barry Silverstein. For too long, the industry has been

Analysts: Personal Stories Most Likely to Influence People Toward COVID-19 Shots
September 10, 2020
By Neozene

The following article originally appeared in FiercePharma and was written by Beth Snyder Bulik As coronavirus vaccines edge closer to market, the next question is how pharma companies and public health authorities will convince people to get them. Civis Analytics decided to test what kind of messages might work. The data firm created five different themed messages and random tested them with 4,000 respondents. They compared the results to the control group in which 73% said they were likely to get a COVID-19 vaccine. The result? Personal stories proved to be the